Pharmacological Treatments for Patients with Treatment-Resistant Depression

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pharmacological management of treatment-resistant depression.

Treatment-resistant depression might be considered as the failure of two families of antidepressant therapy given sequentially at sufficient dosage, for an adequate length of time and with continuous compliance. Patients with treatment-resistant depression should be assessed as though they were new referrals, and factors which may be contributing should be dealt with whenever possible. A sequen...

متن کامل

Pharmacological management of treatment-resistant depression

The management of patients with depression who have failed to respond to antidepressant medication is a common problem in general and old age psychiatry. It has been estimated that about 20-30% of patients with major depression fail to respond to treatment with a single antidepressant drug given in adequate dosage for an appropriate period of rime. At the current time there are many possible wa...

متن کامل

Pharmacological approaches to the challenge of treatment-resistant depression

Although monoaminergic antidepressants revolutionized the treatment of Major Depressive Disorder (MDD) over a half-century ago, approximately one third of depressed patients experience treatment-resistant depression (TRD). Such patients account for a disproportionately large burden of disease, as evidenced by increased disability, cost, human suffering, and suicide. This review addresses the de...

متن کامل

The Pharmacological Frontiers in Treatment Resistant Major Depression

Major depressive disorder (MDD) is a major burden for society, with a year-prevalence of 5% in the adult population. Usually MDD is treated with psychotherapy or serotonergic and noradrenergic antidepressants. With the first antidepressant, often a Selective Serotonin Reuptake Inhibitor (SSRI), 30-40% of patients achieve symptomatic remission. This rate increases to 67% after ≥4 trials with dif...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Pharmaceuticals

سال: 2020

ISSN: 1424-8247

DOI: 10.3390/ph13060116